Osteoporosis

Your daily dose of the clinical news you may have missed.

The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.

Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.

Your daily dose of the clinical news you may have missed.

Less than a quarter of persons with cirrhosis who are diagnosed with osteoporosis are started on treatment, reported researchers.

Women's Health Week (May 14-20, 2023) is an ideal opportunity to review the top research, policy shifts, and potential drug approvals that affect your patient panel.

Denosumab reduced RR of fracture vs alendronate across fracture types, eg, by 36% for hip fracture, by 43% for nonvertebral fractures, and by 30% for vertebral fractures.

Tirzepatide delivers 15.7% weight loss in adults with obesity; remote intervention increases cancer screening in women; women at greater post-MI risk vs men; plus 2 more updates of note.

The updated American College of Physicians osteoporosis treatment guideline is summarized in this topline review for primary care clinicians.

Your daily dose of clinical news you may have missed.